Bergamaschi, R., M. Capobianco, and R. Ravasio. “Budget Impact Analysis of Natalizumab Biosimilar on Pharmaceutical Expenditure for the Treatment of Relapsing-Remitting Multiple Sclerosis in Italy”. AboutOpen, vol. 11, no. 1, June 2024, pp. 48-56, doi:10.33393/ao.2024.3078.